-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
When the great product PD-1 crossed the sea to China and officially opened the era of China's research on biopharmaceuticals, the scientists behind PD-1 have also become the pioneer representatives of China's biopharmaceuticals
.
The birth of a product announces the end
of the mission of a group of people.
After the approval of PD-1, the phased mission of this group of people will end, as the pioneers of the times, they are still leading the development of biological innovative drugs in the industry, or working for big pharmaceutical companies to guide innovation and transformation, or starting a business again to a new battlefield, or staying in the original pharmaceutical companies to continue to shine
。 E drug managers counted the flow of 29 "scientists" from Hengrui, Baekje, Innovda, Junshi, Henlius, and Akeso, and more than half of the PD-1 R&D scientists had already gone to the next battlefield, most of them chose to start new companies again, some of which have been listed on the Hong Kong stock market, and some have become fragrant enterprises
in the primary market.
Where did these scientists go after the development of PD-1? What are you doing now?
1 start: PD-1 first stop
From: PD-1 first stop In April 2013, Song Jing received a grant for his oncology monoclonal antibody drug research and development project, which is an award
from Beijing for outstanding scientific and technological projects for overseas students.
In September of the same year, six people led by Song Jing submitted an invention patent application for tislelizumab, which was roughly the first PD-1 invention patent application filed in China, and BeiGene also occupied the biotechnology highland
as a pioneer representative of Beijing Biopharmaceutical.
Almost at the same time, Chen Bo and Wu Hai of Junshi Biologics submitted a patent application for the invention of trepilimab, and Junshi, as the pioneer team of Shanghai Biopharmaceutical, took the lead in opening the first act
of the PD-1 battlefield.
For more than a year, pharmaceutical companies in the north and south have been competing to develop PD-1
.
In November 2014, Hengrui Pharmaceutical's 9-member R&D team took the lead in submitting the invention patent application
for carrelizumab.
According to the information that has been disclosed, for almost two years, the first battlefield of PD-1 has maintained a "three-legged situation
", you chase me to catch up.
In the second half of 2016, Innovent Biologics and Akeso, two biotechs, squeezed in from a number of R&D companies, and the R&D team of scientists behind Sindilimab and Piampurimab was almost the same, with a small team
of 4~5 people.
The order of entry to the PD-1 First Battlefield is quite representative of the current competitive landscape
.
However, the entrants of each period are not able to stand in the first echelon, and there are always one or two to be squeezed out
.
By 2017, there were many entrants, the research and development space of PD-1 became narrower and narrower, and it was
becoming more and more difficult to obtain invention patents.
During this period, when the latecomers, including Henlius and other newcomers, did not pay attention to the market, but paid more attention to how to go to market
as soon as possible.
2 Fall: Where did the PD-1 scientists go?
FALL: Where did the PD-1 scientists go? Today, the PD-1's battlefield center has transitioned from research and development to commercialization
.
The "scientists" who developed PD-1 also began to look for their next PD-1
.
They withdrew from the PD-1 project, some continued to stay in the original company to hone on other projects, some went to guide the occurrence of innovation to other pioneer enterprises, and some set up their own innovative drugs.
.
.
According to disclosed public information, of the 29 PD-1 scientists counted by E drug managers, more than half of the scientists have left, excluding more than a dozen unknown information, and most have started their own companies
.
Hengrui Pharmaceutical's 9-member team (Yuan Jijun, Qu Xiangdong, Lin Jufang, Ye Xin, Cao Guoqing, Tao Weikang, Zhang Lianshan, Zhang Lei, Yang Li) has gone nearly halfway, Yuan Jijun, Qu Xiangdong and Cao Guoqing, who have made it clear, have all established their own new companies, and Tao Weikang has joined Qilu to lead its global innovative drug research and development
.
At least 3 people from Innovent Biologics (H.
Baruya, Chen Cheng, Liu Xiaolin, Zeng Junwei, Yu Dechao) left, and Liu Xiaolin and Zeng Junwei, who have accurate information, jointly founded their own new company, Pumis Biologics
.
Junshi Biologics' 2-person group, Chen Bo and Wu Hai, all left
.
Chen Boyuan, the founder of Junshi, left in 2016 to found Connoia Biologics, which was listed
on a Hong Kong IPO last year.
Henlius' three-member group (Jiang Weidong, Lin Peihua, Zeng Qiling), has made it clear that co-founder Jiang Weidong is leaving
.
After Jiang Weidong left office, he founded Kangkang Biologics
.
The most stable team is Akeso, and the four PD-1 inventors are also co-founders of Akeso, all of whom hold important positions
in Akeso.
Most of BeiGene's 6-member group (Song Jing, Li Kang, Zhang Tong, Xu Lanlan, Liu Qi, Peng Hao) have not found information, and Li Kang is currently the chief director of BeiGene Biologics, and Zhang Tong is the applicant
of BeiGene's NKp30 antibody patent.
Here's where the PD-1 scientists flowed:
Here's where the PD-1 scientists flowed:Yuan Jijun
Original position: PD-1 scientist of Hengrui Pharmaceutical
Current position: Head of R&D in the field of oncology of Abogen Biosciences
Yuan Jijun left Hengrui Pharmaceutical around 2015 and has worked in several biotechs, and is currently the head of R&D in the field of oncology of Abogen Biosciences, responsible for leading the research of
Abogen Biosciences' oncology pipeline.
Jijun Yuan received his Ph.
D.
from the Department of Biochemistry, School of Life Sciences, Fudan University, Ph.
D.
from The Ohio State University, and a postdoctoral fellow at the University of California, Los Angeles, focusing on the structure and function of
G protein-coupled receptor drug targets.
After returning to China, Yuan Jijun worked in Shanghai Hengrui, responsible for the establishment of drug screening biological models, as well as the research and development of a number of small molecule and large molecule drugs, leading or participating in the research and development
of PD-1 antibodies, PCSK9 antibodies, long-acting insulin and other projects 。 After leaving Hengrui, Yuan Jijun joined GKN in 2015 as vice president and R&D director, responsible for the group's R&D work; In 2016, GKN was established, and as the person in charge, he led the research and development of innovative drugs such as cell therapy, gene therapy, and antibody drugs, during which he led the company to complete the transfer of intellectual property rights for 7 innovative drugs, with a total transaction amount of more than 1 billion yuan
.
In January 2022, he joined Abogen Biosciences as the head of R&D in the field of
oncology.
Yuan Jijun has rich experience in the research and development of oncology drugs, and has published 15 articles and applied for 74 patents
.
Qu to the east
Original position: PD-1 scientist of Hengrui Pharmaceutical
Current position: Founder of Qiyue Biotechnology
After leaving Hengrui Pharmaceutical, Qu Xiangdong founded Qiyue Biologics, which received an angel round of financing of 3 million yuan led by Viva Biologics in July 2017, and then obtained multiple rounds of financing
totaling 100 million yuan.
Qu Xiangdong has more than 20 years of experience in new drug research and development at home and abroad, and worked for Cell Therapeutics, Lilly and Amgen in the United States
from March 1999 to early 2012.
After returning to China in 2012, Qu Xiangdong successively worked for Hailu Biotechnology, the R&D subsidiary of Hengrui Pharmaceutical and Yangtze River Pharmaceutical, and twice formed a team and led a team of more than 60 people to build a biopharmaceutical research and development platform
.
The PD-1 project led by Qu Xiangdong has been approved for marketing, and he has also led the research and development of PD-L1/TGF-β, IL-15 and other biological macromolecules, and has rich experience
in the research and development and management of new protein drugs.
After leaving Hengrui, in July 2017, Qu Xiangdong founded Qiyue Biotechnology, which has pipeline varieties featuring double antibodies and multi-antibodies, CLDN18.
2/PD-L1 bispecific antibodies are expected to become the first domestic approved varieties in the highly competitive CLDN18.
2 track, in addition to the layout of SIRP⍺/PD-L1 double antibodies and other double antibodies, triple antibodies and other varieties
.
Cao Guoqing
Original position: PD-1 scientist of Hengrui Pharmaceutical
Current position: Founder, Chairman & CEO of Minghui Pharmaceutical
After leaving Hengrui Pharmaceutical, Cao Guoqing founded Minghui Pharmaceutical as Chairman and Chief Executive Officer
.
Guoqing Cao received his B.
A.
in Biochemistry from Fudan University, his Ph.
D.
in Biochemistry from The Ohio State University, and a postdoctoral researcher
at Dr.
Michael Brown (Nobel laureate), Dr.
Joseph Goldstein (Nobel Laureate), and Dr.
Helen Hobbs (National Academy of Sciences) at the University of Texas Southwestern Medical Center in Dallas.
After returning to China, he worked for Hengrui Pharmaceutical as vice president of discovery, responsible for preclinical development, translational medicine business development, portfolio management, etc
.
After leaving Hengrui, Cao Guoqing established Minghui Pharmaceutical in April 2018 to engage in early development
.
Tao Weikang
Original position: PD-1 scientist of Hengrui Pharmaceutical
Current position: Vice President of Qilu Pharmaceutical Group and General Manager of Qilu Global Innovative Drug R&D
Tao Weikang has joined Qilu Pharmaceutical as Group Vice President and General Manager of
Qilu Global Innovative Drug R&D.
Comprehensively lead the research and development of Qilu's global innovative drugs, formulate and implement innovative drug research and development strategies, and participate in the planning and implementation
of the company's innovative drug research and development strategy.
Prior to joining Qilu Pharmaceutical, Tao Weikang served as Deputy General Manager and CEO of R&D Center of Hengrui Pharmaceutical, where he participated in the development of
PD-1.
Prior to that, Tao Weikang was engaged in new drug research and development at Merck for more than ten years, serving as a senior researcher and department head, and presided over the research and development and project management
of a number of new anti-cancer drugs.
LIU Xiaolin
Original position: Innovent Biologics PD-1 scientist
Current position: Founder, Chairman & CEO of Pumis Biologics
From working for many large pharmaceutical companies in the United States with more than 30 personal invention patents, to returning to China to join Innovent Biologics, leading the team to successfully launch domestic PD-1 sindilimab.
.
.
After more than 20 years of antibody new drug development, Liu Xiaolin decided to create his own new drug research and development company in Zhuhai, Pumeis Biologics, and served as chairman and CEO
.
Before returning to China, Liu Xiaolin successively served as a R&D executive and director of famous pharmaceutical companies such as Abbott and Adimab in the United States, and led the research and development of the antibody drug Yervoy; Participate in the process optimization
of the world's best-selling antibody new drug Humira.
In 2012, Liu Xiaolin became one of the first "scientists" to return to China for development, and his first stop was Innovent Biologics, where he served as the senior vice president of Innovent Biologics, in charge of process development, new drug research and preclinical research
.
With a new drug R&D and process development team of more than 100 people formed by Liu Xiaolin, Innovent has successfully established a rich product chain
including more than 20 new antibody drugs.
After leaving Innovent Da, Liu Xiaolin co-founded Pumis Biotech
with his team in April 2018.
Four years after its establishment, PumisBio has built a R&D pipeline covering more than ten projects through independent research and development and licensed introduction, more than half of which are bispecific antibody products, and the cell and gene therapy product line
in addition to antibodies.
Zeng Junwei
Original position: Innovent Biologics PD-1 scientist
Current position: Co-founder and Senior Vice President of PumisBio
After leaving Innovent and Liu Xiaolin co-founded Pumis Biologics and served as senior vice president responsible for new drug biology
.
Zeng Junwei is a Ph.
D.
from the University of Oxford and a postdoctoral
fellow at the Shanghai Pasteur Institute, Chinese Academy of Sciences.
He was an associate professor at the Shanghai Pasteur Institute of the Chinese Academy of Sciences, presided over 3 National Natural Science Foundation of China projects as the project leader, and as the core scientist of the joint research project between the Chinese Academy of Sciences and international pharmaceutical companies, he has published more than 30 papers in international academic journals
.
He used to be the director of the new drug research department of Innovent Biologics, responsible for the functional biology research of
new tumor immunotherapy antibody drugs.
During this period, as the deputy leader of the project, he participated in and led the whole process
of anti-tumor antibody drug PD-1 antibody - sindilimab from drug discovery, cell line development to clinical trial application.
Zeng also led the discovery and development
of multiple therapeutic antibodies such as OX40, CD47 and LAG-3.
Chen Bo
Original position: Junshi Biologics PD-1 scientist and one of the founders
Current position: Founder, Chairman & CEO of Connoia Biologics
Chen Bo, a scientist born as a legend in the pharmaceutical circle, is a successful serial entrepreneur, has founded Huaxin Kangyuan Biotechnology, Junshi Biologics one of the founders, and is currently the chairman of the board and CEO
of Kannoya Biologics.
Bo Chen, Ph.
D.
of Albert Einstein College of Medicine, is an expert in antibody drug research and development, and has served as an executive in many large pharmaceutical companies in the United States, such as Eli Lilly, Trellis Bioscience and StemcentRx, with more than 20 years of drug development experience and rich entrepreneurial management experience
.
In 2011, Chen Bo returned to China to start his first entrepreneurship, establishing Huaxin Kangyuan Biotechnology to focus on the development of monoclonal antibody drugs
.
During this period, Chen Bo developed the "humanized anti-Blys antibody", which was applied to the prevention/treatment of diseases caused by excessive proliferation of B cells, such as systemic lupus erythematosus, which once caused a
sensation.
In early 2013, Chen Bo and other founders co-founded Junshi Biologics, and served as general manager, executive director and chief scientist, and successfully developed the first domestic PD-1
during Junshi's period.
Chen Bo gradually withdrew from Junshi
after resigning as general manager in March 2015.
After leaving Junshi, Bo Chen founded Connoia Biologics in 2016 to research innovative monoclonal antibody drugs and other therapeutic protein drugs
.
Launched in Hong Kong in July 2021, Conoia Biologics has an R&D pipeline
of more than 30 products.
Wuhai
Original position: PD-1 scientist of Junshi Biologics
Current position: Undisclosed
Wuhai left Junshi Biologics in October 2020, and his whereabouts have not been disclosed
so far.
Wuhai served as the chief scientific officer of Tuopu Airai, a wholly-owned subsidiary of Junshi, from June 2013 to December 2016, and the deputy general manager
of Junshi from March 2015 to October 2020.
From March 2015 to June 2018, he served as Junshi's Chief Financial Officer
.
During his time at Junshi, Wuhai was responsible for the early research and development of
more than ten antibody drug projects such as Junshi's PD-1 monoclonal antibody and BTLA monoclonal antibody.
Jiang Weidong
Original position: Henlius PD-1 scientist
Current position: Founder and CEO of Concord
Weidong Jiang is a successful serial entrepreneur, following the successful founding of Henlius, he founded and served as CEO
of Concord Biologics.
Weidong Jiang received his bachelor's degree from Zhejiang University, his master's degree in cell biology and genetics from the Shanghai Institute of Cell Biology, Chinese Academy of Sciences, his Ph.
D.
in natural science biology from the University of Giessen, Germany, and his postdoctoral training
at the University of California.
Before returning to China, he successively served as a senior scientist and director in ChemGenics (Millennium), Microcide, Applied Molecular Evolution (Eli Lilly), Catalyst Biosciences and other companies, and has rich experience
in drug research and development 。 In 2009, Jiang Weidong returned to China and co-founded Henlius with his partners as Chief Scientific Officer, led the research and development of a number of projects including PD-1, and in 2011, founded Henlius' US/Taiwan innovative drug R&D subsidiary, which was listed on
the main board of the Hong Kong Stock Exchange in September 2019.
When Henlius gradually grew from Biotech to Biopharma, Jiang Weidong decided to start a business again and established ChemBio
in 2021.
This time, Jiang Weidong chose to focus on the field of tumor immunity and lay out new molecules such as immune cell agonist prodrug molecules
and multifunctional antibodies.
